Pulmonx Corp (LUNG)

$7.3

-0.22

(-2.93%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Pulmonx Corp

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 14.53M → 19.27M (in $), with an average increase of 8.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -16.19M → -13.88M (in $), with an average increase of 8.0% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 78.4%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 72.5% return, outperforming this stock by 156.6%

Performance

  • $7.11
    $7.42
    $7.30
    downward going graph

    2.6%

    Downside

    Day's Volatility :4.18%

    Upside

    1.62%

    downward going graph
  • $7.21
    $14.84
    $7.30
    downward going graph

    1.23%

    Downside

    52 Weeks Volatility :51.42%

    Upside

    50.81%

    downward going graph

Returns

PeriodPulmonx CorpSector (Health Care)Index (Russel 2000)
3 Months
-43.84%
1.1%
0.0%
6 Months
-10.48%
12.5%
0.0%
1 Year
-35.73%
6.9%
2.2%
3 Years
-84.08%
14.3%
-23.0%

Highlights

Market Capitalization
291.1M
Book Value
$3.07
Earnings Per Share (EPS)
-1.6
Wall Street Target Price
16.2
Profit Margin
-88.6%
Operating Margin TTM
-72.2%
Return On Assets TTM
-20.84%
Return On Equity TTM
-44.69%
Revenue TTM
68.7M
Revenue Per Share TTM
1.81
Quarterly Revenue Growth YOY
25.0%
Gross Profit TTM
39.9M
EBITDA
-60.4M
Diluted Eps TTM
-1.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.85
EPS Estimate Next Year
-1.54
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Pulmonx Corp(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 121.92%

Current $7.30
Target $16.20

Company Financials

FY18Y/Y Change
Revenue
20.0M
-
Net Income
-18.5M
↑ 244.16%
Net Profit Margin
-92.38%
-
FY19Y/Y Change
Revenue
32.6M
↑ 62.94%
Net Income
-20.7M
↑ 12.04%
Net Profit Margin
-63.52%
↑ 28.86%
FY20Y/Y Change
Revenue
32.7M
↑ 0.42%
Net Income
-32.2M
↑ 55.68%
Net Profit Margin
-98.47%
↓ 34.95%
FY21Y/Y Change
Revenue
48.4M
↑ 47.91%
Net Income
-48.7M
↑ 50.98%
Net Profit Margin
-100.51%
↓ 2.04%
FY22Y/Y Change
Revenue
53.7M
↑ 10.84%
Net Income
-58.9M
↑ 21.09%
Net Profit Margin
-109.8%
↓ 9.29%
FY23Y/Y Change
Revenue
68.7M
↑ 27.98%
Net Income
-60.8M
↑ 3.26%
Net Profit Margin
-88.6%
↑ 21.2%
Q3 FY22Q/Q Change
Revenue
13.5M
↓ 3.21%
Net Income
-13.8M
↓ 5.81%
Net Profit Margin
-102.13%
↑ 2.82%
Q4 FY22Q/Q Change
Revenue
15.4M
↑ 14.24%
Net Income
-14.3M
↑ 3.58%
Net Profit Margin
-92.6%
↑ 9.53%
Q1 FY23Q/Q Change
Revenue
14.5M
↓ 5.77%
Net Income
-15.9M
↑ 11.04%
Net Profit Margin
-109.12%
↓ 16.52%
Q2 FY23Q/Q Change
Revenue
17.2M
↑ 18.29%
Net Income
-16.2M
↑ 2.11%
Net Profit Margin
-94.19%
↑ 14.93%
Q3 FY23Q/Q Change
Revenue
17.7M
↑ 2.76%
Net Income
-14.9M
↓ 8.0%
Net Profit Margin
-84.33%
↑ 9.86%
Q4 FY23Q/Q Change
Revenue
19.3M
↑ 9.11%
Net Income
-13.9M
↓ 6.79%
Net Profit Margin
-72.04%
↑ 12.29%
FY18Y/Y Change
Total Assets
15.0M
↑ 924.73%
Total Liabilities
182.3M
↑ 11831.22%
FY19Y/Y Change
Total Assets
53.5M
↑ 256.58%
Total Liabilities
240.9M
↑ 32.12%
FY20Y/Y Change
Total Assets
263.7M
↑ 392.61%
Total Liabilities
37.6M
↓ 84.4%
FY21Y/Y Change
Total Assets
235.2M
↓ 10.82%
Total Liabilities
41.9M
↑ 11.6%
FY22Y/Y Change
Total Assets
193.7M
↓ 17.65%
Total Liabilities
39.7M
↓ 5.4%
FY23Y/Y Change
Total Assets
179.0M
↓ 7.6%
Total Liabilities
60.6M
↑ 52.85%
Q3 FY22Q/Q Change
Total Assets
202.2M
↓ 4.95%
Total Liabilities
38.7M
↓ 4.5%
Q4 FY22Q/Q Change
Total Assets
193.7M
↓ 4.22%
Total Liabilities
39.7M
↑ 2.45%
Q1 FY23Q/Q Change
Total Assets
201.3M
↑ 3.92%
Total Liabilities
57.3M
↑ 44.54%
Q2 FY23Q/Q Change
Total Assets
193.1M
↓ 4.05%
Total Liabilities
59.2M
↑ 3.18%
Q3 FY23Q/Q Change
Total Assets
185.0M
↓ 4.19%
Total Liabilities
59.3M
↑ 0.19%
Q4 FY23Q/Q Change
Total Assets
179.0M
↓ 3.28%
Total Liabilities
60.6M
↑ 2.3%
FY18Y/Y Change
Operating Cash Flow
-18.4M
↑ 296.63%
Investing Cash Flow
200.0K
↓ 846.24%
Financing Cash Flow
12.1M
↑ 129.78%
FY19Y/Y Change
Operating Cash Flow
-20.8M
↑ 12.89%
Investing Cash Flow
-14.2M
↓ 7216.5%
Financing Cash Flow
45.6M
↑ 276.58%
FY20Y/Y Change
Operating Cash Flow
-30.6M
↑ 47.52%
Investing Cash Flow
12.7M
↓ 189.19%
Financing Cash Flow
234.8M
↑ 414.77%
FY21Y/Y Change
Operating Cash Flow
-41.4M
↑ 35.11%
Investing Cash Flow
-46.3M
↓ 464.38%
Financing Cash Flow
4.5M
↓ 98.1%
FY22Y/Y Change
Operating Cash Flow
-45.1M
↑ 8.93%
Investing Cash Flow
-4.2M
↓ 90.87%
Financing Cash Flow
2.4M
↓ 45.71%
Q3 FY22Q/Q Change
Operating Cash Flow
-10.7M
↑ 11.74%
Investing Cash Flow
44.0K
↓ 97.88%
Financing Cash Flow
906.0K
↑ 591.6%
Q4 FY22Q/Q Change
Operating Cash Flow
-9.8M
↓ 8.24%
Investing Cash Flow
-727.0K
↓ 1752.27%
Financing Cash Flow
67.0K
↓ 92.6%
Q1 FY23Q/Q Change
Operating Cash Flow
-12.6M
↑ 28.94%
Investing Cash Flow
574.0K
↓ 178.95%
Financing Cash Flow
20.7M
↑ 30825.37%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 37.59%
Investing Cash Flow
-813.0K
↓ 241.64%
Financing Cash Flow
92.0K
↓ 99.56%

Technicals Summary

Sell

Neutral

Buy

Pulmonx Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pulmonx Corp
Pulmonx Corp
-15.79%
-10.48%
-35.73%
-84.08%
-80.87%
Stryker Corporation
Stryker Corporation
-3.86%
30.27%
12.73%
26.98%
78.91%
Dexcom, Inc.
Dexcom, Inc.
-1.59%
63.45%
11.22%
31.69%
366.88%
Boston Scientific Corp.
Boston Scientific Corp.
7.32%
46.46%
42.68%
72.49%
95.05%
Abbott Laboratories
Abbott Laboratories
-2.84%
13.74%
-1.71%
-12.8%
36.06%
Medtronic Plc
Medtronic Plc
-3.97%
14.22%
-10.66%
-38.23%
-7.98%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pulmonx Corp
Pulmonx Corp
NA
NA
NA
-1.85
-0.45
-0.21
NA
3.07
Stryker Corporation
Stryker Corporation
40.64
40.64
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
64.48
64.48
1.8
2.25
0.09
0.04
NA
13.16
Abbott Laboratories
Abbott Laboratories
33.52
33.52
5.99
4.31
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.81
25.81
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pulmonx Corp
Pulmonx Corp
Buy
$291.1M
-80.87%
NA
-88.6%
Stryker Corporation
Stryker Corporation
Buy
$127.4B
78.91%
40.64
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
366.88%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$101.4B
95.05%
64.48
11.18%
Abbott Laboratories
Abbott Laboratories
Buy
$186.7B
36.06%
33.52
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.9B
-7.98%
25.81
13.0%

Institutional Holdings

  • PRIMECAP Management Company

    14.55%

  • FMR Inc

    8.53%

  • BlackRock Inc

    8.03%

  • Point72 Asset Management, L.P.

    7.55%

  • Morgan Stanley - Brokerage Accounts

    5.87%

  • Vanguard Group Inc

    5.32%

Corporate Announcements

  • Pulmonx Corp Earnings

    Pulmonx Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company’s first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp

Organization
Pulmonx Corp
Employees
279
CEO
Mr. David A. Lehman
Industry
Health Technology

Discover More

FAQs